Trikafta (Vertex) is expected to face US generic competition from 2037. Patents run to about 2037. Cystic fibrosis. Excludes the successor Alyftrek ($0.8B).
Trikafta's US exclusivity date is based on patent-expiry estimate. It is estimated from patent expiry rather than a fixed entry date, so it may move as patents are challenged or extended. It is a small-molecule drug, so copies are generics. Generic launches usually take most of the US volume within months.
Trikafta is 86% of Vertex's 2025 revenue ($10.3B of $12.0B).
Bars show each company's tracked drugs as a share of its total 2025 revenue. Trikafta is highlighted.